Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/32855
Başlık: Assessment of immune responses to hepatitis A vaccination in children aged 1 and 2 years
Yazarlar: Uludağ Üniversitesi/Tıp Fakültesi/Pediatri Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/ Mikrobiyoloji Anabilim Dalı.
Çelebi, Solmaz
Hacımustafaoğlu, Mustafa Kemal
Albayrak, Yücehan
Sinirtaş, Ayşe Melda
7006095295
6602154166
36165377200
54788212600
Anahtar kelimeler: General & internal medicine
Hepatitis A vaccine
Seroprevalence
Safety
Immunogenicity
Children
Maternal antibody
Immunogenicity
Seroprevalence
Infants
Safety
Need
Yayın Tarihi: 2013
Yayıncı: TÜBİTAK
Atıf: Çelebi, S. vd. (2013). “Assessment of immune responses to hepatitis A vaccination in children aged 1 and 2 years”. Turkish Journal of Medical Sciences, 43(4), 617-624.
Özet: Aim: Hepatitis A can be prevented by vaccination. The aim of this study was to determine seropositivity for hepatitis A before vaccination in healthy children 12 and 24 months of age and compare seroconversion rates after vaccination between these 2 groups. Materials and methods: Forty-nine children aged 1 year (Group 1) and 51 children aged 2 years (Group 2) were included in the study. Inactive hepatitis A vaccine (Avaxim, 80 antigenic subtypes, 0.5 mL) were administered to every child in 2 doses, 6 months apart. Anti-hepatitis A virus (HAV) IgG and IgM antibodies were detected by Architect HAVAb-IgG and HAVAb-IgM (Abbott, Wiesbaden, Germany) test kits. Results: Nine percent of the children were seropositive for anti-HAV IgG before vaccination. The seroconversion rate at 2 weeks was 34% and 44% in Group 1 and Group 2, respectively. At 4 weeks the seroconversion rate was 87.7% and 90.1% in Group 1 and Group 2, respectively. All of the children who completed the vaccination program were seropositive at 28 weeks (after the second dose). No serious adverse reaction was observed in any of the children. Conclusion: It was determined that Avaxim, including 80 antigen units, is safe and immunogenic in healthy children 12 and 24 months of age.
URI: https://doi.org/10.3906/sag-1206-99
https://journals.tubitak.gov.tr/medical/vol43/iss4/22/
http://hdl.handle.net/11452/32855
ISSN: 1300-0144
1303-6165
Koleksiyonlarda Görünür:Scopus
TrDizin
Web of Science

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
Çelebi_vd_2013.pdf67.39 kBAdobe PDFKüçük resim
Göster/Aç


Bu öğe kapsamında lisanslı Creative Commons License Creative Commons